Combining potential cancer-induced anemia therapeutic targets, such as TGF-β, VEGF signaling, hepcidin, IL-6, CD71, CCL2/CCR2, GM-CSF, and exercise, with ICIs could therefore be an effective therapeutic approach (Fig. 3). This evidence concerns the gene TFRC and anemia.